Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This is a cluster randomised trial evaluating the safety of co-administering Azithromycin
alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for
LF.
Treatment will be provided as a single dose Mass Drug Administration (MDA) to the whole
community. Communities will be randomised to receive either treatment with IDA and
Azithromycin on the same day or separately.
Active monitoring for adverse events will be conducted and the frequency of adverse events
compared between individuals receiving combined MDA or separate MDA.